Genomic loss of one HLA haplotype was first described in 2009 in patients relapsing after haplo-HCT for AML and myelodysplastic syndrome (MDS) (either non-T-cell depleted or using purified CD34+ cells with subsequent DLI) [14]. Here, CD34 is linked to myelodysplastic syndrome.